Logo image of CMRA

COMERA LIFE SCIENCES HOLDING (CMRA) Stock Fundamental Analysis

NASDAQ:CMRA - Nasdaq - US20037C1080 - Common Stock - Currency: USD

0.2227  -0.02 (-8.88%)

After market: 0.09 -0.13 (-59.59%)

Fundamental Rating

1

Taking everything into account, CMRA scores 1 out of 10 in our fundamental rating. CMRA was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of CMRA have multiple concerns. CMRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CMRA has reported negative net income.
In the past year CMRA has reported a negative cash flow from operations.
CMRA Yearly Net Income VS EBIT VS OCF VS FCFCMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -439.19%, CMRA is not doing good in the industry: 98.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -439.19%
ROE N/A
ROIC N/A
ROA(3y)-318.65%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMRA Yearly ROA, ROE, ROICCMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 500 -500 1K -1K

1.3 Margins

Looking at the Gross Margin, with a value of 74.17%, CMRA belongs to the top of the industry, outperforming 84.17% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for CMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMRA Yearly Profit, Operating, Gross MarginsCMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

1

2. Health

2.1 Basic Checks

CMRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
CMRA has less shares outstanding than it did 1 year ago.
There is no outstanding debt for CMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CMRA Yearly Shares OutstandingCMRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M
CMRA Yearly Total Debt VS Total AssetsCMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -36.24, we must say that CMRA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -36.24, CMRA is not doing good in the industry: 95.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -36.24
ROIC/WACCN/A
WACC11.01%
CMRA Yearly LT Debt VS Equity VS FCFCMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 5M -5M

2.3 Liquidity

CMRA has a Current Ratio of 0.46. This is a bad value and indicates that CMRA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.46, CMRA is not doing good in the industry: 95.50% of the companies in the same industry are doing better.
A Quick Ratio of 0.46 indicates that CMRA may have some problems paying its short term obligations.
CMRA has a worse Quick ratio (0.46) than 95.17% of its industry peers.
Industry RankSector Rank
Current Ratio 0.46
Quick Ratio 0.46
CMRA Yearly Current Assets VS Current LiabilitesCMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.05% over the past year.
Looking at the last year, CMRA shows a very strong growth in Revenue. The Revenue has grown by 95.59%.
EPS 1Y (TTM)13.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.93%
Revenue 1Y (TTM)95.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMRA Yearly Revenue VS EstimatesCMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMRA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMRA Price Earnings VS Forward Price EarningsCMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMRA Per share dataCMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMERA LIFE SCIENCES HOLDING

NASDAQ:CMRA (11/16/2023, 8:21:40 PM)

After market: 0.09 -0.13 (-59.59%)

0.2227

-0.02 (-8.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2022-11-10/bmo
Earnings (Next)N/A N/A
Inst Owners1.03%
Inst Owner Change0%
Ins Owners46.33%
Ins Owner Change0%
Market Cap6.85M
AnalystsN/A
Price TargetN/A
Short Float %0.04%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.59
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.04
BVpS-0.05
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -439.19%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.17%
FCFM N/A
ROA(3y)-318.65%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.39%
Cap/Sales 10.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.46
Quick Ratio 0.46
Altman-Z -36.24
F-Score4
WACC11.01%
ROIC/WACCN/A
Cap/Depr(3y)69.7%
Cap/Depr(5y)N/A
Cap/Sales(3y)17.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)95.59%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%114.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-151.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-160.03%
OCF growth 3YN/A
OCF growth 5YN/A